Skip to Content

'
Xinqun Li, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Instructor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

My current research interests focus on identifiction and validation of new cancer targets involved in growth factor receptor-mediated signal transduction pathways.  I hope to find better cancer molecular therapeutic approaches for potential clinical applications, particularly, in breast cancer patients.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 36
Houston, TX 77030
Room Number: Y6.5306
Phone: 713-745-3561
Fax: 713-745-3562
Email: xinquli@mdanderson.org

Education & Training

Degree-Granting Education

2001 Shanghai Second Medical University, Shanghai, P.R., China, PHD, Medicine in Surgery
1989 Shanghai Second Medical University, Shanghai, P.R., China, MD, Medicine

Postgraduate Training

6/2002-10/2006 Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Fan
1996-2001 Excellent M.D. Award Program, Shanghai Second Medical University, Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, P.R., China, Dr. Shi
8/1989-8/1996 Clinical Residency, Out patient department and emergency ward in surgery medicine, Burn Institute of Shanghai, Burn Center of Ruijin Hospital, Shanghai Second Medical University, Shanghai, P.R., China, Dr. Liao

Selected Publications

Peer-Reviewed Original Research Articles
1. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GG, Hung MC, Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene. e-Pub 1/2012.
2. Luwor RB, Lu Y, Li X, Liang K, Fan Z. Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer Lett 306(1):85-91, 7/1/2011. e-Pub 3/15/2011. PMCID: PMC3102794.
3. Pan T, Li X, Jankovic J. The association between Parkinson's disease and melanoma. Int J Cancer 128(10):2251-60, 5/15/2011. e-Pub 3/14/2011. PMID: 21207412.
4. Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan T. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 19(3):163-74, 2011. e-Pub 7/22/2011. PMID: 21778691.
5. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18(5):423-35, 11/16/2010. PMCID: PMC3022383.
6. Li X, Lu Y, Pan T, Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 6(8):1066-77, 11/2010. PMCID: PMC3039478.
7. Wu Y, Li X, Xie W, Jankovic J, Le W, Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int 57(3):198-205, 10/2010. e-Pub 5/28/2010. PMID: 20546814.
8. Li X, Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 70(14):5942-52, 7/15/2010. PMCID: PMC2933174.
9. Lu Y, Li X, Lu H, Fan Z. 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. PLoS One 5(12):e15823, 2010. e-Pub 12/29/2010. PMCID: PMC3012113.
10. Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther 7(5):1207-17, 5/2008. PMID: 18483308.
11. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67(17):8240-7, 9/2007. PMID: 17804738.
12. Lu Y, Liang K, Li X, Fan Z. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer 6:63, 2007. PMCID: PMC2117021.
13. Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB, Fan Z. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol 70(3):1045-52, 9/2006. e-Pub 6/2006. PMID: 16782806.
14. Li X, Lu Y, Jin W, Liang K, Mills GB, Fan Z. Autophosphorylation of Akt at Threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. J Biol Chem 281(19):13837-43, 5/2006. e-Pub 3/2006. PMID: 16549426.
15. Li X, Luwor R, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25(4):525-35, 1/2006. PMID: 16170346.
16. Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 579(30):6716-20, 12/2005. e-Pub 11/2005. PMID: 16313906.
17. Li X, Lu Y, Liang K, Liu B, Fan Z. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res 7(5):R589-97, 2005. e-Pub 5/2005. PMCID: PMC1242125.
18. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24(27):4433-41, 2004. PMID: 15806152.
19. Li X, Shi JX. Local expression of interleukin-12 mRNA in grafted skin rats. Chinese Journal of Burns 16:292-295, 2000.
20. Li X, Shi JX. Study of Immunosuppressive Effect of Intermingled Skin Grafting after Burn. Chinese Journal of Traumatology 15:444-447, 1999.
21. Li X, Shi JX. The structual characterization of transforming growth factor beta and its biologic functions during wound healing. Chinese Journal of Current Practical Medicine 2:119-122, 1999.
22. Li X, Shi JX. The depression of burn patient out of hospital. Acta Uniserisitatis Medicinalis Secondae Shanghai 17:74-75, 1997.
23. Li X, Liao ZJ, Shi JX. A study of electric burns. Chinese Journal of Traumatology 12:397-398, 1996.
24. Li X, Xiao YR. The healing effect of WS-Frequency Spectrum Effect Physiatrics Apparatus to the wound surface in mice. Shanghai Medical Journal 62:3678-3682, 1994.

Last updated: 4/9/2013